Expression of ARs in triple negative breast cancer tumors: A potential prognostic factor?

11Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Background/aim: In light of the controversial published literature, this study aims to examine the potential prognostic role of AR immunohistochemical expression in triple negative breast cancer (TNBC). Patients and methods: Ninety patients with TNBC were included in this study; the associations between AR expression (Allred score), clinicopathological variables (stage, grade, histological subtype, tumor size, nodal status, age at diagnosis, Ki67 expression, and p53 expression), and overall survival were evaluated. Results: AR expression was not associated with stage, grade, histological subtype, tumor size, nodal status, age at diagnosis, Ki67 expression, and p53 expression. AR immunopositivity was not associated with overall survival either at the univariate or at the multivariate Cox regression analysis (multivariate hazard ratio =0.66, 95% confidence interval: 0.26–1.70, P=0.393). Conclusion: AR expression does not seem to play a prognostic role in TNBC.

Cite

CITATION STYLE

APA

Giannos, A., Filipits, M., Zagouri, F., Brandstetter, A., Tsigginou, A., Sotiropoulou, M., … Dimitrakakis, C. (2015). Expression of ARs in triple negative breast cancer tumors: A potential prognostic factor? OncoTargets and Therapy, 8, 1843–1847. https://doi.org/10.2147/OTT.S78254

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free